Probiotix Health

Probiotix Health Net Margin

The Net Profit Margin of Probiotix Health (PBX.AQ) as of Nov 3, 2026 is -44.98 %. In the previous year, Net Profit Margin was -44.65 % — a change of 0.74% (lower).

Net Margin

-44.98 %

YoY

0.74%

Last updated:

Net Profit Margin of Probiotix Health is 2024 -44.98 % . Net Profit Margin of Probiotix Health was 2023 -44.65 % . It decreases by 0.74% lower compared to the previous year.

For Probiotix Health, the net margin of -45.0% is down versus -1.6% a few years ago.

The Probiotix Health Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
-142.48 GBP
Jan 1, 2020
-1.62 GBP
Jan 1, 2021
3.31 GBP
Jan 1, 2022
-17.80 GBP
Jan 1, 2023
-44.65 GBP
Jan 1, 2024
-44.98 GBP
The Probiotix Health Net Margin history
YEARNet MarginYoY
-44.98 %+0.74%
-44.65 %+150.85%
-17.80 %-637.96%
3.31 %-304.27%
-1.62 %-98.86%
-142.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Probiotix Health Stock analysis

What does Probiotix Health do? ProBiotix Health PLC develops probiotics to tackle cardiovascular disease and lifestyle conditions, focusing on cholesterol reduction through its LP-LDL ingredient. The company commercializes LP-LDL as an ingredient and in CholBiome products, including CholBiome, CholBiome X3, CholBiome BP, and CholBiome VH, which improve blood lipid profiles and blood pressure. ProBiotix leverages its OptiScreen and OptiBiotic platform technologies to identify metabolic pathways for potential health benefits across various diseases. The firm targets healthcare providers, supplement manufacturers, and consumers seeking natural solutions for cardiovascular health. ProBiotix Health PLC's revenue streams include selling LP-LDL as an ingredient to manufacturers and direct sales of CholBiome products under white-label and own-label arrangements. The CholBiome range serves segments such as cardiovascular health management, lifestyle disease prevention, and natural health supplements. The company's pipeline, driven by OptiScreen and OptiBiotic, supports future product development in metabolic health and disease-specific applications. The firm's business model centers on developing and commercializing probiotic solutions for cardiovascular health, with LP-LDL as the core product. CholBiome products are positioned for consumers and healthcare partners, while the OptiScreen and OptiBiotic platforms enable expansion into new therapeutic areas. ProBiotix's revenue comes from ingredient sales and branded product lines targeting health-conscious individuals and industry partners in the probiotic and supplement markets. Probiotix Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Probiotix Health stock

Net Profit Margin of Probiotix Health is -44.98 % in 2024.

Net Profit Margin of Probiotix Health changed from -44.65 % to -44.98 %, representing a 0.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Probiotix Health since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Probiotix Health with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Probiotix Health

All Key Metrics — Probiotix Health